Literature DB >> 16211313

Comparative genomics on ROR1 and ROR2 orthologs.

Masuko Katoh1, Masaru Katoh.   

Abstract

Transmembrane proteins with extracellular Frizzled domain, such as ROR1, ROR2, MUSK, MFRP, FZD1, FZD2, FZD3, FZD4, FZD5, FZD6, FZD7, FZD8, FZD9 and FZD10, are key molecules for WNT signaling network. Here, comparative integromics analyses on ROR1 and ROR2 orthologs were performed by using bioinformatics. Zebrafish ror2 gene, consisting of nine exons, was identified within CR-450684.3 genome sequence. CV490605.1 EST corresponded to the 5'-end of zebrafish ror2 mRNA, and BM533602.1 EST corresponded to the 3'-end. Zebrafish ror2 gene was found to encode a 939-aa transmembrane protein, showing 71.7% and 56.2% total amino-acid identity with human ROR2 and ROR1, respectively. Immunoglobulin-like domain, Frizzled domain, Kringle domain within the extracellular region, tyrosine kinase domain, Ror homology C-terminal (RORHC) domain and juxta-C-terminal LLGD motif within the cytoplasmic region were conserved among vertebrate ROR1 and ROR2 orthologs. SH2 binding site within the RORHC domain was conserved among vertebrate ROR2 orthologs, but not among vertebrate ROR1 orthologs. ROR1 mRNA was expressed in embryonic stem (ES) cells, infant brain, renal cancer, and colon cancer. ROR2 mRNA was expressed in parathyroid, testis, uterus, and also in diffuse type gastric cancer with signet ring cell features. ROR2 promoter rather than ROR1 promoter was more evolutionarily conserved. WNT5A and ROR family receptors, co-expressed in ES cells and gastric cancer, are implicated in the planar cell polarity (PCP) pathway. ROR1 and ROR2 are the pharmacogenomics targets in the fields of stem cell biology and oncology.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16211313     DOI: 10.3892/or.14.5.1381

Source DB:  PubMed          Journal:  Oncol Rep        ISSN: 1021-335X            Impact factor:   3.906


  15 in total

1.  Mouse resistin modulates adipogenesis and glucose uptake in 3T3-L1 preadipocytes through the ROR1 receptor.

Authors:  Beatriz Sánchez-Solana; Jorge Laborda; Victoriano Baladrón
Journal:  Mol Endocrinol       Date:  2011-11-10

2.  Mutated KRAS results in overexpression of DUSP4, a MAP-kinase phosphatase, and SMYD3, a histone methyltransferase, in rectal carcinomas.

Authors:  Jochen Gaedcke; Marian Grade; Klaus Jung; Jordi Camps; Peter Jo; Georg Emons; Anastasia Gehoff; Ulrich Sax; Markus Schirmer; Heinz Becker; Tim Beissbarth; Thomas Ried; B Michael Ghadimi
Journal:  Genes Chromosomes Cancer       Date:  2010-11       Impact factor: 5.006

Review 3.  Wnt signaling through the Ror receptor in the nervous system.

Authors:  Iveta M Petrova; Martijn J Malessy; Joost Verhaagen; Lee G Fradkin; Jasprina N Noordermeer
Journal:  Mol Neurobiol       Date:  2013-08-30       Impact factor: 5.590

Review 4.  Epithelial-to-mesenchymal and mesenchymal-to-epithelial transitions in the colon.

Authors:  Ferenc Sipos; Orsolya Galamb
Journal:  World J Gastroenterol       Date:  2012-02-21       Impact factor: 5.742

5.  A significant association exists between receptor tyrosine kinase-like orphan receptor 2 gene variants and the OPG/RANKL ratio in human plasma.

Authors:  S Ermakov; S Trofimov; I Malkin; G Livshits
Journal:  Osteoporos Int       Date:  2011-11-05       Impact factor: 4.507

6.  Wnt5a induces ROR1/ROR2 heterooligomerization to enhance leukemia chemotaxis and proliferation.

Authors:  Jian Yu; Liguang Chen; Bing Cui; George F Widhopf; Zhouxin Shen; Rongrong Wu; Ling Zhang; Suping Zhang; Steven P Briggs; Thomas J Kipps
Journal:  J Clin Invest       Date:  2016-02       Impact factor: 14.808

7.  Safety of targeting ROR1 in primates with chimeric antigen receptor-modified T cells.

Authors:  Carolina Berger; Daniel Sommermeyer; Michael Hudecek; Michael Berger; Ashwini Balakrishnan; Paulina J Paszkiewicz; Paula L Kosasih; Christoph Rader; Stanley R Riddell
Journal:  Cancer Immunol Res       Date:  2014-10-29       Impact factor: 11.151

8.  Antisera induced by infusions of autologous Ad-CD154-leukemia B cells identify ROR1 as an oncofetal antigen and receptor for Wnt5a.

Authors:  Tetsuya Fukuda; Liguang Chen; Tomoyuki Endo; Li Tang; Desheng Lu; Januario E Castro; George F Widhopf; Laura Z Rassenti; Mark J Cantwell; Charles E Prussak; Dennis A Carson; Thomas J Kipps
Journal:  Proc Natl Acad Sci U S A       Date:  2008-02-19       Impact factor: 11.205

9.  Hypoxia induces phenotypic plasticity and therapy resistance in melanoma via the tyrosine kinase receptors ROR1 and ROR2.

Authors:  Michael P O'Connell; Katie Marchbank; Marie R Webster; Alexander A Valiga; Amanpreet Kaur; Adina Vultur; Ling Li; Meenhard Herlyn; Jessie Villanueva; Qin Liu; Xiangfan Yin; Sandy Widura; Janelle Nelson; Nivia Ruiz; Tura C Camilli; Fred E Indig; Keith T Flaherty; Jennifer A Wargo; Dennie T Frederick; Zachary A Cooper; Suresh Nair; Ravi K Amaravadi; Lynn M Schuchter; Giorgos C Karakousis; Wei Xu; Xiaowei Xu; Ashani T Weeraratna
Journal:  Cancer Discov       Date:  2013-10-08       Impact factor: 39.397

Review 10.  The Wnts of change: How Wnts regulate phenotype switching in melanoma.

Authors:  Marie R Webster; Curtis H Kugel; Ashani T Weeraratna
Journal:  Biochim Biophys Acta       Date:  2015-11-04
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.